<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19865">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01725711</url>
  </required_header>
  <id_info>
    <org_study_id>R402-98</org_study_id>
    <nct_id>NCT01725711</nct_id>
  </id_info>
  <brief_title>Osseointegrated Prostheses for the Rehabilitation of Amputees</brief_title>
  <acronym>OPRA</acronym>
  <official_title>Osseointegrated Prostheses for the Rehabilitation of Amputees.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GÃ¶teborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrum</source>
  <oversight_info>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with transfemoral amputations (TFA) frequently experience problems related to the
      use of socket-suspended prostheses 1-3. These problems increase with short or deformed
      stumps 4. The potential for improvement is substantial. Based on the very good long-term
      results with osseointegrated titanium implants for edentulous patients 5, osseointegrated
      hearing aids 6, cranio-facial prostheses 7 and prostheses for thumb-amputated patients 8,
      the clinical development of osseointegrated prostheses for TFA started in 1990, in
      Gothenburg, Sweden. The concept has gradually been modified and improved. In 1999, a
      prospective clinical trial began.

      The hypothesis is that the treatment will improve quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 1999</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Q-TFA Prosthetic Use Score</measure>
    <time_frame>0,1,2,3,5,7,10,15,20 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy variable is the change in Q-TFA Prosthetic Use Score as compared baseline.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Transfemoral Amputation</condition>
  <arm_group>
    <arm_group_label>Implant System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPRA Implant System</intervention_name>
    <arm_group_label>Implant System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Transfemoral amputation

        Exclusion Criteria:

          -  Transfemoral amputation due to vascular disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>VG</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 13, 2012</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
